By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
The most effective method to Shake Hands Expertly: A Bit by bit Guide - 2Manual for Financial plan Agreeable PC
- 3Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- 4Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- 5Chicago reports first rabies-positive dog in 61 years. What we know.
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- The largest sun of 2026 rises today as Earth draws closest to our parent star
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- Starfront Observatories: A haven for distant stargazers
- Vote In favor of Your Number one Game Control center
- The capacity to understand people on a profound level: Exploring Life's Intricacies
- Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- Amateur's Manual for Venture Strategies for Tenderfoots
